Analysts Lift Targets as CNK Reports Thursday
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Cinemark Holdings, the second-largest cinema chain in the United States, releases its third-quarter results on November 6 with the stock down 2.6% on the week at $38.51 and several analysts moving their price targets higher in the hours around the announcement.
The most striking development this week has been the speed and breadth of analyst target upgrades. Wells Fargo raised its target from $34 to $42 on November 4 while holding its Equal-Weight rating. Wedbush moved from $45 to $46, keeping Outperform. StoneX lifted from $40 to $45, also at Buy. Morgan Stanley had already moved from $40 to $45 on November 2. The direction is consistent: even analysts who are not outright bullish on the stock are marking up their views on what it is worth. The consensus target now stands at roughly $42, about 9% above the current share price. That gap reflects a Street that broadly expects more from the business than the present valuation implies, though several of the larger houses remain at neutral ratings rather than recommending fresh buying.
The factor data adds texture to that view. Forward earnings estimates have risen sharply over the past year, with CNK ranking in the 98th percentile on 12-month forward EPS growth versus history. Near-term momentum factors are also strong, with 30-day EPS momentum in the 89th percentile. The EV/EBITDA multiple has drifted down slightly over the past 30 days, to roughly 8.9x, suggesting the multiple compression has not kept pace with the earnings upgrade cycle. The bull case centres on a richer 2026 film slate, record concessions revenue per customer of $8.58, and a leverage ratio of 2.6x that is conservative enough to support growth spending. The bear case focuses on the international segment, where attendance fell roughly 7% in the most recent quarter and EBITDA margins ran at just 10.7%, raising questions about whether the domestic recovery story holds up globally.
Short positioning has eased considerably since the previous note published earlier this week. Short interest fell a further 1.4% over the past week to 6.5% of the free float, extending a decline that began from a mid-October peak above 9 million shares. That reduction has continued; the data for November 3 shows shares short at approximately 7.5 million, still down sharply from the 9 million handle seen in the week of October 19. Borrow conditions are extremely relaxed: availability stands at over 1,200%, meaning there are roughly 12 times as many shares available to lend as are currently borrowed. Cost to borrow has actually fallen 16% over the past week to 0.42%, which is negligible in absolute terms. There is no sign of squeeze pressure or any constraint on new short positions being established.
Options positioning has shifted meaningfully toward calls over recent weeks. The put/call ratio has dropped to 0.70, well below its 20-day average of 0.83 and roughly 0.75 standard deviations below that mean. Through late September and early October, the PCR was running above 1.1, with put demand clearly dominant. That balance flipped sharply after mid-October, and call activity has been relatively stronger ever since. The 52-week low on the PCR is 0.19, so current levels are not extreme, but the direction of travel matches the analyst upgrade cycle: options traders have grown less defensive as the results date has approached.
Ownership is relatively stable. BlackRock reported a 14.6% stake in its most recent filing. Orbis Investment Management holds 13.1% and has been building, moving from a 9.8% position disclosed earlier to 13.0% in its February 2026 filing. No activist 13D positions are on the register. All holders are on 13G filings, indicating passive or non-activist intent, though as with all 13D/G disclosures, positions are stated as of last filing and holders who drop below 5% are not required to file again.
The print on November 6 will test whether the upgraded analyst targets reflect a genuine read on the quarter, or whether the international softness flagged in the bear case creates a gap between domestic strength and overall results.
Stocks in this article
See the live data behind this article on ORTEX.
Open CNK on ORTEX →How this article was generated
- Generated
- 4 Nov 2026, 19:30
- Data as of
- 4 Nov 2026, 19:23
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.